Virologic Characterization of Multidrug-Resistant Cytomegalovirus Infection in 2 Transplant Recipients Treated with MaribavirSTRASFELD, Lynne; LEE, Ingi; TATAROWICZ, Walter et al.The Journal of infectious diseases. 2010, Vol 202, Num 1, pp 104-108, issn 0022-1899, 5 p.Article

Stereoselective Phosphorylation of Cyclopropavir by pUL97 and Competitive Inhibition by MaribavirGENTRY, Brian G; KAMIL, Jeremy P; COEN, Donald M et al.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 8, pp 3093-3098, issn 0066-4804, 6 p.Article

Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantSUNWEN CHOU; MAROUSEK, Gail I.Journal of virology. 2008, Vol 82, Num 1, pp 246-253, issn 0022-538X, 8 p.Article

Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replicationGERSHBURG, Edward; KE HONG; PAGANO, Joseph S et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 5, pp 1900-1903, issn 0066-4804, 4 p.Article

Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavirCHOU, Sunwen; MAROUSEK, Gail I; SENTERS, Anne E et al.Journal of virology. 2004, Vol 78, Num 13, pp 7124-7130, issn 0022-538X, 7 p.Article

Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infectionHAKKI, Morgan; DRUMMOND, Coyne; HOUSER, Benjamin et al.Antiviral research. 2011, Vol 92, Num 2, pp 313-318, issn 0166-3542, 6 p.Article

Maribavir Inhibits Epstein-Barr Virus Transcription in Addition to Viral DNA ReplicationWANG, Fu-Zhang; ROY, Debasmita; GERSHBURG, Edward et al.Journal of virology. 2009, Vol 83, Num 23, pp 12108-12117, issn 0022-538X, 10 p.Article

Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy AdultsGOLDWATER, D. Ronald; DOUGHERTY, Carolyn; SCHUMACHER, Mary et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 5, pp 1794-1798, issn 0066-4804, 5 p.Article

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnetDREW, W. Lawrence; MINER, Richard C; MAROUSEK, Gail I et al.Journal of clinical virology. 2006, Vol 37, Num 2, pp 124-127, issn 1386-6532, 4 p.Article

Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infectionREITSMA, Justin M; TERHUNE, Scott S.Antiviral research. 2013, Vol 100, Num 2, pp 321-327, issn 0166-3542, 7 p.Article

Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under MaribavirSUNWEN CHOU.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 1, pp 81-85, issn 0066-4804, 5 p.Article

Cytomegalovirus UL97 kinase mutations that confer maribavir resistanceSUNWEN CHOU; VAN WECHEL, Laura C; MAROUSEK, Gail I et al.The Journal of infectious diseases. 2007, Vol 196, Num 1, pp 91-94, issn 0022-1899, 4 p.Article

Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirusSUNWEN CHOU; MAROUSEK, Gail I.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 10, pp 3470-3472, issn 0066-4804, 3 p.Article

Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivoCHOU, Sunwen; HAKKI, Morgan; VILLANO, Stephen et al.Antiviral research. 2012, Vol 95, Num 2, pp 88-92, issn 0166-3542, 5 p.Article

Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsMA, Joseph D; NAFZIGER, Anne N; VILLANO, Stephen A et al.Antimicrobial agents and chemotherapy. 2006, Vol 50, Num 4, pp 1130-1135, issn 0066-4804, 6 p.Article

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trialMARTY, Francisco M; LJUNGMAN, Per; EINSELE, Hermann et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 4, pp 284-292, issn 1473-3099, 9 p.Article

Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavirMCGREGO, Alistair; YEON CHOI, K; XIAOHONG CUI et al.Antiviral research. 2008, Vol 78, Num 3, pp 250-259, issn 0166-3542, 10 p.Article

Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavirBOUTOLLEAU, David; BURREL, Sonia; AGUT, Henri et al.Antiviral research. 2011, Vol 91, Num 1, pp 32-35, issn 0166-3542, 4 p.Article

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients : a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. CommentaryMEHTA, Jayesh; WINSTON, Drew J; CHAO, Nelson et al.Blood. 2008, Vol 111, Num 11, issn 0006-4971, 5265-5266, 5403-5410 [10 p.]Article

Focus on new drugs in development against human cytomegalovirusEMERY, Vincent C; HASSAN-WALKER, Aycan F.Drugs (Basel). 2002, Vol 62, Num 13, pp 1853-1858, issn 0012-6667, 6 p.Article

Maribavir : A Novel Antiviral Agent with Activity Against CytomegalovirusTROFE, Jennifer; POTE, Lindsey; WADE, Erin et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1447-1457, issn 1060-0280, 11 p.Article

Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled TrialWINSTON, D. J; SALIBA, F; NAVASA, M et al.American journal of transplantation (Print). 2012, Vol 12, Num 11, pp 3021-3030, issn 1600-6135, 10 p.Article

A Randomized, Double-Blind, Pharmacokinetic Study of Oral Maribavir with Tacrolimus in Stable Renal Transplant RecipientsPESCOVITZ, M. D; BLOOM, R; PIRSCH, J et al.American journal of transplantation (Print). 2009, Vol 9, Num 10, pp 2324-2330, issn 1600-6135, 7 p.Article